Neuromyelitis optica spectrum disorders: A nationwide Portuguese clinical epidemiological study.

[1]  Jacqueline Palace,et al.  Worldwide Incidence and Prevalence of Neuromyelitis Optica , 2020, Neurology.

[2]  J. M. Behne,et al.  Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide , 2020, Frontiers in Neurology.

[3]  K. Kyvik,et al.  Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998–2008, 2007–2014) , 2019, Brain and behavior.

[4]  Ramil Hakim,et al.  Epidemiology of NMOSD in Sweden from 1987 to 2013 , 2019, Neurology.

[5]  X. Montalban,et al.  Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates , 2018, Multiple sclerosis.

[6]  J. Frederiksen,et al.  Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark , 2018, Neurology.

[7]  T. Bek,et al.  Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region , 2018, Acta neurologica Scandinavica.

[8]  I. Nakashima,et al.  Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan , 2017, Neurology.

[9]  S. Eskandarieh,et al.  Neuromyelitis optica spectrum disorders in Iran. , 2017, Multiple sclerosis and related disorders.

[10]  K. Dear,et al.  Incidence and prevalence of NMOSD in Australia and New Zealand , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  B. Weinshenker,et al.  Neuromyelitis Spectrum Disorders , 2017, Mayo Clinic proceedings.

[12]  F. Paul,et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin , 2016, Journal of Neuroinflammation.

[13]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[14]  B. Weinshenker,et al.  Neuromyelitis Optica Spectrum Disorders , 2014, Current Neurology and Neuroscience Reports.

[15]  K. Fujihara,et al.  Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders , 2014, Neurology.

[16]  F. Paul,et al.  Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS) , 2013, Journal of Neurology.

[17]  B. Weinshenker,et al.  Effects of age and sex on aquaporin-4 autoimmunity. , 2012, Archives of neurology.

[18]  M. Papadopoulos,et al.  Aquaporin 4 and neuromyelitis optica , 2012, The Lancet Neurology.

[19]  Jacqueline Palace,et al.  Myasthenia gravis and neuromyelitis optica spectrum disorder , 2012, Neurology.

[20]  P C O'Brien,et al.  The clinical course of neuromyelitis optica (Devic’s syndrome) , 1999, Neurology.

[21]  M. Leite,et al.  Prevalence of neuromyelitis optica spectrum disorder in the multi-ethnic Penang Island, Malaysia, and a review of worldwide prevalence. , 2018, Multiple sclerosis and related disorders.